• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Treanda, Bendeka (bendamustine hydrochloride)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Treanda, Bendeka (bendamustine hydrochloride)

  • Profile

Profile

Contact Information

Contact: Teva Pharmaceuticals
Website: https://www.treandahcp.com/; https://www.bendekahcp.com/

Currently Enrolling Trials

    Show More

    General Information

    Treanda and Bekinda are rationally designed purine analog and alkylator hybrid. The product damages the DNA in cancer cells, which leads to the normal path of cell death (apoptosis). It also stops cancer cells from dividing to create new cancer cells.

    Treanda/Bekinda is specifically indicated for:

    • the treatment of chronic lymphocytic leukemia where efficacy relative to first line therapies other than chlorambucil has not been established
    • indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

    Treanda and Bekinda have two main differences:

    The first difference is that it takes less time to administer the same dosage of Bendeka compared to Treanda.

    • An infusion of Bendeka can be administered over 10 minutes whereas an infusion of Treanda must be administered over 60 minutes.

    The second difference is that Bendeka is compatible with polycarbonate or acrylonitrile-butadiene-styrene (ABS)-containing infusion equipment, and Treanda injection is not.

    • Treanda Injection cannot be used with closed system transfer devices (CSTDs), adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS) as significant absorption of the active ingredient bendamustine to surfaces containing these ingredients will occur.

    Treanda/Bendeka both come as a ready made solution for intravenous administration. Treanda also is available as a powder that requires mixing with sterile water before diluting. 

    The recommended initial dose of the drug for the treatment of non-Hodgkin's lymphoma is 120 mg/m2 administered intravenously over 60 minutes on days one and two of a 21-day cycle, up to eight cycles. Treanda administration should be delayed in the event of a Grade 4 hematologic toxicity or clinically significant > Grade 2 non-hematologic toxicity.
    Dose modifications for hematologic toxicity: reduce the dose to 90 mg/m2 on days one1 and two of each cycle. If Grade 4 toxicity recurs, reduce the dose to 60 mg/m2 on days one and two of each cycle.
    Dose modifications for non-hematologic toxicity: reduce the dose to 90 mg/m2 on days one and two of each cycle. If Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m2 on days one and two of each cycle.

    The recommended initial dose of the drug for the treatment of chronic lymphocytic leukemia is 100 mg/m2 administered intravenously over 30 minutes on days one and two of a 28-day cycle, up to six cycles. Treanda administration should be delayed in the event of Grade 4 hematologic toxicity or clinically significant >Grade 2 non-hematologic toxicity.
    Dose modifications for hematologic toxicity: reduce the dose to 50 mg/m2 on days one and two of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 25 mg/m2 on days one and two of each cycle.
    Dose modifications for non-hematologic toxicity: reduce the dose to 50 mg/m2 on days one and two of each cycle.

    Mechanism of Action

    Treanda/Bendeka contains bendamustine hydrochloride, an alkylating drug. Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. However, the exact mechanism of action of bendamustine remains unknown.

    Side Effects

    Adverse events associated with the use of Treanda/Bendeka for chronic lymphocytic leukemia may include, but are not limited to, the following:

    • Pyrexia
    • Nausea
    • Vomiting
    • Asthenia
    • Fatigue
    • Malaise
    • Weakness
    • Dry mouth
    • Somnolence
    • Cough
    • Constipation
    • Headache
    • Mucosal inflammation
    • Stomatitis

    Adverse events associated with the use of Treanda/Bendeka for the treatment of non-Hodgkin's lymphoma may include, but are not limited to, the following:

    • Nausea
    • Fatigue
    • Vomiting
    • Diarrhea
    • Pyrexia
    • Ratigue
    • Rebrile neutropenia
    • Pneumonia
    • Hypokalemia
    • Dehydration.

    Clinical Trial Results

    FDA approval for Treanda/Bendeka for the treatment of chronic lymphocytic leukemia was based on the results of an open-label, randomized, controlled multicenter trial in 301 previously-untreated patients with Binet Stage B or C (Rai Stages I - IV) CLL requiring treatment. The subjects received either bendamustine HCL at 100 mg/m2, administered intravenously over a period of 30 minutes on days one and two or chlorambucil at 0.8 mg/kg administered orally on days one and 15 of each 28-day cycle. Efficacy endpoints were objective response rate and progression-free survival. The overall response rate was 59 percent in the bendamustine HCL arm compared to 26 percent in the chlorambucil arm (p).

    FDA approval for the treatment of non-Hodgkin's lymphoma was based on the results of a single arm study of 100 subjects with indolent B-cell NHL that had progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. All subjects received bendamustine HCL intravenously at a dose of 120 mg/m2, on days one and two of a 21-day treatment cycle. They were treated for up to eight cycles. Overall response rate was seen in 74 of the subjects (64.3 percent). The median duration of response was 9.2 months.

    Approval Date: 2008-10-01
    Company Name: Teva Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing